



AIDS 2018

Value-Based Financing of Integrated Care for Persons Living with HIV



PED 566

An actionable approach to engage payers on value-drive, indicator-based financing

S.J.Vermeersch¹, R. Demeester², S. Callens³, S. De Wit⁴, L. Annemans⁵

Context and objectives

Delivery of **patient-centered, integrated care** is paramount to **meet the HIV challenge**:

- reducing undiagnosed patient numbers
- improving the continuum of care (90-90-90 treatment targets)
- achieving the 'fourth' health-related quality of life treatment target through management of comorbidities and self-perceived quality of life.

Integrated care systems, however, **face the same (financial) pressures as the healthcare system as a whole** as payers struggle to balance costs and outcomes.

We developed and deployed, in the context of Belgian AIDS Reference center (ARC) financing, **an integrated framework** to:

- shift the discussion **from costs to value and value for money**.
- quantify value impact to **bolster value messages**.
- translate value messages to **practical value-driven financing approaches**.

Conclusions

We developed **an actionable approach** to **shift financing towards a value-driven, indicator-based model**. Value-driven healthcare models foster **high-quality, solidarity-based and sustainable healthcare systems**.

Methods & results

1

An expert consensus on key ARC value drivers

1

Prevent new infections

2

Reduce the number of undiagnosed

3

Link to care: visiting a healthcare provider after a positive diagnosis

4

Retain in care: having viral load measured at least once per year

5

Achieve and maintain virological control: viral load < 200 copies/ml

6

Support quality of life

7

Manage and reduce comorbidities

8

Maintain sexual and reproductive health

9

Perform data collection

10

Drive and execute research


2

A modelling approach to quantify & extrapolate value elements^{a,b}

	Current effort	Reduced effort	Additional effort	Additional effort + reinforced outreach
Undiagnosed	11%	12%	10%	8%
Treated	94%	92%	97%	97%
Viral load < 200 c/ml	96%	94%	98%	98%
Linked to care	98,2%	95%	99%	99%
Retained in care	97,9%	97%	99%	99%
PrEP (patients)	1 500	1 000	2 633	2 633
New diagnoses 2020 (patients)	899	1 121	603	513
New diagnoses 2030 (patients)	1 165	1 985	410	319
Annual budget 2020 (euro)	203 M€	202 M€	207 M€	209 M€
Annual budget 2030 (euro)	254 M€	296 M€	211 M€	204 M€

3

A logical framework approach to define value-based indicators



What does the indicator measure?

When/how often is the indicator evaluated?

Why should the indicator be included?

Should the indicator be disaggregated?

How is the indicator calculated?

What are the indicator's strengths and weaknesses?

4

A translation to value-driven financing

^a See poster/abstract PEC330 – *Quantifying the impact of reduced investments in integrated HIV care delivery in Belgium*^b Detailed model description in *Vermeersch et al. Acta Clin Belg 73 (1),54-67*

This study, independently performed by the authors, was funded by Gilead Sciences Belgium bvba/sprl